Niu Ji1, Pin Meng1, Bingchao Xu1, Xinyu Zhou1. 1. Department of Neurology, The First Affiliated Hospital of Kangda College of Nanjing Medical University Lianyungang 222000, Jiangsu, China.
Abstract
BACKGROUND: To investigate the efficacy and safety of pramipexole in Parkinson's disease with anxiety or depression by analyzing the randomized clinical trials (RCTs). METHODS: National Library of Medicine (PubMed), Cochrane Library of EMBASE, CNKI, VIP and Wanfang database were retrieved to conduct a meta-analysis. We performed sensitivity analysis to assess the efficacy and safety of pramipexole in Parkinson's disease with anxiety or depression. RESULTS: In our study, the results showed that the efficiency was significantly improved in patients with Parkinson's disease of the experimental group (fixed effect model, SMD = 3.45, 95% CI = [2.50, 4.76]). The HAMD score of experimental group was lower than that of control group. Moreover, adverse events of experimental group were lower than that of control group. CONCLUSIONS: The research demonstrated that pramipexole may improve the efficacy and HAMD score of Parkinson's disease with anxiety or depression. Due to the limited number of included studies, more RCTs are needed to investigate the effect of pramipexole in Parkinson's disease with anxiety or depression. AJTR
BACKGROUND: To investigate the efficacy and safety of pramipexole in Parkinson's disease with anxiety or depression by analyzing the randomized clinical trials (RCTs). METHODS: National Library of Medicine (PubMed), Cochrane Library of EMBASE, CNKI, VIP and Wanfang database were retrieved to conduct a meta-analysis. We performed sensitivity analysis to assess the efficacy and safety of pramipexole in Parkinson's disease with anxiety or depression. RESULTS: In our study, the results showed that the efficiency was significantly improved in patients with Parkinson's disease of the experimental group (fixed effect model, SMD = 3.45, 95% CI = [2.50, 4.76]). The HAMD score of experimental group was lower than that of control group. Moreover, adverse events of experimental group were lower than that of control group. CONCLUSIONS: The research demonstrated that pramipexole may improve the efficacy and HAMD score of Parkinson's disease with anxiety or depression. Due to the limited number of included studies, more RCTs are needed to investigate the effect of pramipexole in Parkinson's disease with anxiety or depression. AJTR
Authors: Karen I Connor; Hilary C Siebens; Brian S Mittman; Donna K McNeese-Smith; David A Ganz; Frances Barry; Lisa K Edwards; Michael G McGowan; Eric M Cheng; Barbara G Vickrey Journal: BMC Neurol Date: 2020-12-02 Impact factor: 2.474
Authors: Luca Vignatelli; Corrado Zenesini; Laura M B Belotti; Elisa Baldin; Giuseppe Bonavina; Giovanna Calandra-Buonaura; Pietro Cortelli; Carlo Descovich; Giovanni Fabbri; Giulia Giannini; Maria Guarino; Roberta Pantieri; Giuseppe Samoggia; Cesa Scaglione; Susanna Trombetti; Roberto D'Alessandro; Francesco Nonino Journal: Mov Disord Date: 2020-12-02 Impact factor: 9.698